Skip to main content

CIDP

1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
lipoic acidPhase 21 trial
Active Trials
NCT00962429Completed7Est. Jan 2013
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
IVIgN/A
CSL Behring
CSL BehringIL - Bradley
1 program
IVIgN/A1 trial
Active Trials
NCT05614128Terminated2Est. Sep 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Oregon Therapeuticslipoic acid
CSL BehringIVIg

Clinical Trials (2)

Total enrollment: 9 patients across 2 trials

NCT00962429Oregon Therapeuticslipoic acid

Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy

Start: Feb 2009Est. completion: Jan 20137 patients
Phase 2Completed
NCT05614128CSL BehringIVIg

Validation of Cutaneous Nerve Demyelination in Diagnosis and Treatment of CIDP

Start: Feb 2023Est. completion: Sep 20242 patients
N/ATerminated

Related Jobs

Senior Manager, US HCP Marketing

argenxargenx
Boston, MA, USA
4w ago
$128K - $176K/yr

Senior Clinical Development Lead Neuroimmunology, Immunology & Indication Expansion, WCH

BiogenBiogen
San Francisco, CA
1mo ago
$254K - $349K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.